Kobayashi Y, Sato T, Nagai T, et al. - Worse long-term clinical results accompanied by increased systemic inflammatory activity were observed in relation to increased soluble interleukin 2 receptor (sIL-2R) among cardiac sarcoidosis (CS) patients.

• This study involved 83 consecutive patients with CS with available serum sIL-2R data.

• A composite of advanced atrioventricular block, ventricular tachycardia or ventricular fibrillation, heart failure hospitalization, and all-cause death was the primary outcome.

• Higher serum sIL-2R concentrations (>538 U/mL, the median) were significantly associated with elevated incidence of primary outcome.

• A higher sIL-2R was independently related to an elevated subsequent risk of adverse events (HR 3.71), even post-adjustment for significant covariates.

• sIL-2R levels showed significant correlation with inflammatory activity in lymph nodes but not the myocardium.